These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Mechanisms of incretin effects on plasma lipids and implications for the cardiovascular system. Xiao C; Dash S; Lewis GF Cardiovasc Hematol Agents Med Chem; 2012 Dec; 10(4):289-94. PubMed ID: 22827289 [TBL] [Abstract][Full Text] [Related]
25. CARDIOVASCULAR OUTCOME TRIALS OF THE INCRETIN-BASED THERAPIES: WHAT DO WE KNOW SO FAR? Mora PF; Johnson EL Endocr Pract; 2017 Jan; 23(1):89-99. PubMed ID: 27819769 [TBL] [Abstract][Full Text] [Related]
27. Incretin-Based Antidiabetic Agents for the Management of Non-Alcoholic Fatty Liver Disease. Nakouti T; Karagiannis AK; Tziomalos K; Cholongitas E Curr Vasc Pharmacol; 2015; 13(5):649-57. PubMed ID: 25412688 [TBL] [Abstract][Full Text] [Related]
28. Novel Therapeutic Approaches in Diabetes. Gallwitz B Endocr Dev; 2016; 31():43-56. PubMed ID: 26824365 [TBL] [Abstract][Full Text] [Related]
29. Current and emerging therapies: an overview of incretin-based therapy in the management of type 2 diabetes. Pratley RE J Am Acad Nurse Pract; 2008 Nov; 20 Suppl 1():7-11. PubMed ID: 19402254 [No Abstract] [Full Text] [Related]
30. The place of GLP-1-based therapy in diabetes management: differences between DPP-4 inhibitors and GLP-1 receptor agonists. Eckerle Mize DL; Salehi M Curr Diab Rep; 2013 Jun; 13(3):307-18. PubMed ID: 23479200 [TBL] [Abstract][Full Text] [Related]
31. Role of incretin-based therapy in hospitalized patients with type 2 diabetes. Gracia-Ramos AE J Diabetes Investig; 2020 Mar; 11(2):508-509. PubMed ID: 31529777 [TBL] [Abstract][Full Text] [Related]
32. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797 [TBL] [Abstract][Full Text] [Related]
33. Molecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity. Yaribeygi H; Sathyapalan T; Sahebkar A Life Sci; 2019 Oct; 234():116776. PubMed ID: 31425698 [TBL] [Abstract][Full Text] [Related]
34. Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study. Knapen LM; de Jong RG; Driessen JH; Keulemans YC; van Erp NP; De Bruin ML; Leufkens HG; Croes S; de Vries F Diabetes Obes Metab; 2017 Mar; 19(3):401-411. PubMed ID: 27883260 [TBL] [Abstract][Full Text] [Related]
35. Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study. Ueda P; Wintzell V; Melbye M; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Svanström H; Pasternak B Diabetologia; 2021 Oct; 64(10):2204-2214. PubMed ID: 34254177 [TBL] [Abstract][Full Text] [Related]
36. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Nauck MA; Meier JJ Lancet Diabetes Endocrinol; 2016 Jun; 4(6):525-36. PubMed ID: 26876794 [TBL] [Abstract][Full Text] [Related]
37. Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting. Garber AJ Am J Manag Care; 2010 Aug; 16(7 Suppl):S187-94. PubMed ID: 20809667 [TBL] [Abstract][Full Text] [Related]
38. Incretin-based therapies in 2021 - Current status and perspectives for the future. Rizzo M; Nauck MA; Mantzoros CS Metabolism; 2021 Sep; 122():154843. PubMed ID: 34333000 [No Abstract] [Full Text] [Related]
39. [Potential of pharmacological modulation of level and activity incretins on diabetes mellitus type 2]. Spasov AA; Chepljaeva NI Biomed Khim; 2015; 61(4):488-96. PubMed ID: 26350740 [TBL] [Abstract][Full Text] [Related]
40. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors. Morales J Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]